News

Compounding pharmacies are crimping sales of Novo Nordisk's obesity drug Wegovy by making what are essentially copies of the ...
GoodRx reports on identifying real Wegovy pens, which come in five colors and lack dose selectors. Counterfeits pose health ...
Novo Nordisk's downward guidance Tuesday sent its stock diving 20%, even as new leadership remains bullish on the company's ...
The new novel, out July 29 from Flatiron Books, follows a group of mothers whose children are enrolled at the ...
Semaglutide, the active ingredient in Ozempic and Wegovy, is a glucagon-like peptide-1 (GLP-1) receptor agonist taken as a once-weekly injection.
India is emerging as a key player in the global weight management industry, driven by a rising obesity crisis and the ...
When telehealth executive Andrew Dudum received a email wishing him a happy Father’s Day last month, he took it as a sign of the strong relationship he’d cultivated with a key partner. He did not see ...
Wegovy, the GLP-1 medication to treat obesity from Lilly competitor Novo Nordisk, will still be covered under plans managed by CVS Caremark, along with a few other medications that are generally ...
A Wegovy pen is placed against a bright concept background in this image shared by GoodRx Health; the product photo is ...
Several anti-obesity drugs, including Ozempic, Wegovy and Mounjaro, have created buzz in the Indian markets. But are they really approved for use in India? What are their side-effects? And how much do ...
Popular diabetes and weight loss drug, semaglutide- the active ingredient in 'Wegovy' and 'Ozempic'- may lower dementia risk in people with type 2 diabetes. The corresponding study was published in ...
A new study finds four factors that may make it more likely for some people to experience successful weight loss from using GLP-1Rs such as Ozempic or Wegovy.